What changed in December 2025, and what did not?
On 1 December 2025, the World Health Organization published its first global guideline on GLP-1 therapies for obesity in adults. The main change is that WHO says these therapies may be used as long-term treatment for adults living with obesity within comprehensive, continuing care. This is a conditional rather than a strong recommendation and is supported by moderate-certainty evidence. WHO added a second conditional recommendation: intensive, structured behavioural therapy may be offered alongside treatment, but evidence for its added benefit is of low certainty [1, 2, 4].
What did not change matters just as much. The guideline does not say that anyone wanting to lose weight should start an injection. It does not identify one medicine as best for everyone and does not provide a dosing table or a switching protocol. It does not remove healthy eating, physical activity or follow-up, and it does not present medicine as a stand-alone answer. The recommendation places pharmacotherapy within care for a chronic, relapsing disease, not a quick weight-loss course with a predictable endpoint [1, 2, 3, 4].
A headline claiming that WHO approved weight-loss injections for everyone would therefore be misleading. More accurately, WHO considered benefits, harms, feasibility and equity, then issued two conditional recommendations that require individual decisions and follow-up. For mechanisms and adverse effects, use the GLP-1 medicines guide rather than treating this update as a duplicate drug guide [1, 4].
Who is covered, and which medicines are included?
The guideline addresses adults living with obesity. In WHO's accompanying explanation, obesity for this guideline means a body mass index of 30 or above. That defines the population considered by the recommendation; it is not a complete individual diagnosis or an invitation to judge health from one number. Medical history, obesity complications, current medicines, capacity for follow-up and personal goals all contribute to a clinical decision. The guideline does not automatically extend the recommendation to everyone whose weight is above a preferred range but below the obesity threshold [1, 2, 3].
The medicines reviewed by name are liraglutide, semaglutide and tirzepatide. Tirzepatide acts at both GIP and GLP-1 receptors, but the guideline groups these medicines under the term GLP-1 therapies when stating the recommendation. Separate systematic reviews were conducted for each medicine before the guideline group considered them as a class. Cochrane reviews found weight-loss efficacy, while also showing that certainty varies by outcome and that very long-term and independent evidence is limited in important areas [4, 5, 6, 7].
Pregnancy is outside the recommendation. The precise point is not that the guideline proved the medicines safe in pregnancy and then rejected them. Pregnant women were excluded because these therapies have not been tested in this population sufficiently for inclusion. A possibility of pregnancy or plans for pregnancy must be discussed with the prescriber before starting or continuing treatment. Mounjaro and Wegovy are not synonyms for the entire class, and finding a brand name in a search does not identify the right treatment [1, 2, 3].
What do conditional recommendations and evidence certainty mean?
Recommendation strength and certainty of evidence are related, but they are not the same. Moderate certainty means that the panel has reasonable confidence in estimates of some benefits and harms, although further research may change the size of an effect or the understanding of particular outcomes. Low certainty means greater uncertainty. A conditional recommendation means the balance of desirable and undesirable consequences, values and preferences, resources, equity and feasibility will not be identical for every person or every health system [1, 4].
The first recommendation, on long-term therapy, is conditional and supported by moderate-certainty evidence. Why, when weight reduction is evident? WHO recorded gaps in longer-term efficacy and safety data and in evidence about titration, maintenance and discontinuation, alongside affordability, health-system readiness and the risk of widening unequal access. This does not mean treatment is ineffective. It means that demonstrated benefit does not automatically turn the decision into one rule for everyone [1, 2, 4, 5, 6, 7].
The second recommendation, on adding intensive behavioural therapy, is conditional and supported by low-certainty evidence. WHO found a signal that it may improve outcomes, but direct evidence for the added effect with medicine was insufficient for a strong recommendation. General advice about food and activity should be distinguished from an intensive programme with structured goals, sessions and monitoring. Low certainty does not make food and activity unimportant; it prevents a promise that one programme will add the same benefit for everyone [1, 4, 8].
Long term does not mean an automatic lifetime decision
WHO uses “long term” to mean continuous treatment for six months or longer under the regulatory definition used in the guideline. This does not mean that every person must continue forever, and it does not establish one stopping date. It means that obesity is a chronic, relapsing disease and treatment should not be presented as a brief course with a predictable endpoint. At the same time, WHO identifies maintenance and discontinuation evidence as a continuing research priority [1, 3, 4].
Withdrawal studies explain the caution. The STEP 1 extension observed substantial regain after semaglutide withdrawal in a subset of participants, while SURMOUNT-4 found substantial regain after tirzepatide was withdrawn compared with continued treatment. These studies do not prove that every person will regain the same amount or that stopping is forbidden. They do rule out a simple promise that a few months of injections will be followed by effortless permanent stability [9, 10].
Discussion should begin before the first prescription. What is the health goal? How will response, adverse effects and nutrition be monitored? What happens if treatment is unsuitable, unavailable or the person wants to discuss stopping? Do not stop, reduce, increase or change medicine on your own. For a switching question, read the guide to switching from Wegovy to Mounjaro, which explains why there is no direct dose conversion, rather than inventing a protocol from a general guideline [1, 4, 9, 10].
Food, activity and follow-up remain part of care
The second recommendation says that an adult living with obesity who is prescribed a GLP-1 therapy may be offered intensive behavioural therapy as part of a multimodal plan. The guideline describes structured goals for food and activity, regular contact and assessment of progress. Because evidence for the added effect is of low certainty, this should not be converted into a fixed number of sessions or one standard programme presented as a universal condition for success [1, 4].
In practice, a person should not have to earn medicine through a punitive diet, and reduced appetite does not make nutritional quality irrelevant. Support should fit health, culture, resources and time. It can focus on sustainable meals, suitable activity, sleep and psychological wellbeing without blame. A joint nutrition and obesity advisory highlights assessment of dietary patterns, gastrointestinal effects, nutrient risk, strength and muscle, and the person's social context during treatment [8].
For practical food guidance, the article on eating with Mounjaro and Wegovy covers smaller meals, protein, fibre and fluids without doses or punishment. The guide to protecting muscle while losing weight explains protein, movement and resistance work without claiming that every loss of lean tissue can be prevented. The WHO guideline places these details correctly as support within medical care, not a punishment or a promise of one uniform result [1, 3, 8].
Equitable access and medicine quality are part of the picture
WHO did not consider efficacy in isolation from real-world delivery. The conditional recommendation reflects affordability, production and supply limits, readiness for follow-up, and the possibility that treatment could reach some groups more readily than others. An effective medicine in trials does not mean that every health system can provide it safely and fairly to everyone who may qualify. WHO calls for broader access without widening disparities and transparent prioritisation based on need and expected benefit [1, 2, 4].
For a reader in Egypt, this does not prove that a particular medicine is currently registered or available, and it does not justify relying on an advertisement or sales page. Availability changes, and a global guideline is not a local stock list. High demand has also been associated with falsified and substandard products. WHO warned about falsified semaglutide batches and explained that an unknown product may contain an incorrect amount, contaminants or substituted ingredients [2, 11].
Safety begins with assessment, a prescription, a licensed supply source and a traceable package, not social-media photographs of pens. Do not buy an unknown injection, use another person's pen or change treatment because of a shortage or sales claim. If the package or source is doubtful, do not use it; ask a pharmacist, the prescriber and the appropriate regulator. This reduces the danger of an unverified source but cannot provide an absolute guarantee for any supply channel [2, 3, 11].
What this means for you
If you live with obesity and are considering a GLP-1 therapy, this update provides a current global basis for discussing medicine as a possible long-term option within comprehensive care. It is not permission to start treatment, a prescription for a named product or a guarantee that benefit outweighs harm in your case. Bring a list of medicines and supplements, previous treatment attempts, symptoms and chronic conditions, together with health goals. Ask why treatment is being considered, how follow-up will work and what would prompt continuation or reassessment [1, 3, 4].
If you already use treatment, do not stop it or change the dose, schedule or product because of a guideline headline. Contact the prescriber if symptoms interfere with eating or drinking, weight is falling unintentionally or faster than planned, or pregnancy or another medicine needs discussion. The guideline is not an emergency protocol; a severe or sudden symptom needs care appropriate to its urgency rather than waiting for routine follow-up [1, 3].
At La Rose, you can book a weight-management assessment with the medical team in Maadi, or in Fifth Settlement on Wednesday. The author, Dr Youssef Hagag, is a content contributor and medical researcher in clinical nutrition, not a clinic doctor available for booking. Booking is with the medical team and begins with assessment of treatment suitability and discussion of follow-up, nutrition and activity, without a promised result or starting or stopping medicine because of an article [1, 4, 8].
